Ocular Therapeutix (OCUL) Price/OCF Ratio: History & Chart

Ocular Therapeutix, Inc.(OCUL)

Biotechnology · Bedford, MA

$7.34+0.09 (+1.24%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.

Bedford, MA

325 employees

www.ocutx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Pravin U. Dugel

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Ocular Therapeutix, Inc. (OCUL)	$1.61B	N/A	N/A	N/A	N/A
Septerna Inc (SEPN)vs ›	$1.61B	15.17	12.78	12.78	12.78
Omnicell, Inc. (OMCL)vs ›	$1.61B	8.83	11.82	9.67	19.67
uniQure N.V. (QURE)vs ›	$1.60B	N/A	3.53	3.57	3.57
Alphatec Holdings, Inc. (ATEC)vs ›	$1.62B	28.68	53.85	68.03	68.03
ANI Pharmaceuticals, Inc. (ANIP)vs ›	$1.63B	8.58	9.49	12.49	26.43
Kestra Medical Technologies, Ltd. (KMTS)vs ›	$1.59B	N/A	N/A	N/A	N/A
Stoke Therapeutics, Inc. (STOK)vs ›	$1.57B	N/A	27.23	27.23	27.23
Syndax Pharmaceuticals, Inc. (SNDX)vs ›	$1.54B	N/A	74.54	74.54	74.54
Innoviva, Inc. (INVA)vs ›	$1.54B	8.03	9.12	8.67	7.22

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Ocular Therapeutix, Inc. (OCUL)

$1.61B

N/A

Septerna Inc (SEPN)vs ›

$1.61B

15.17

12.78

Omnicell, Inc. (OMCL)vs ›

$1.61B

8.83

11.82

9.67

19.67

uniQure N.V. (QURE)vs ›

$1.60B

N/A

3.53

3.57

Alphatec Holdings, Inc. (ATEC)vs ›

$1.62B

28.68

53.85

68.03

ANI Pharmaceuticals, Inc. (ANIP)vs ›

$1.63B

8.58

9.49

12.49

26.43

Kestra Medical Technologies, Ltd. (KMTS)vs ›

$1.59B

N/A

Stoke Therapeutics, Inc. (STOK)vs ›

$1.57B

N/A

27.23

Syndax Pharmaceuticals, Inc. (SNDX)vs ›

$1.54B

N/A

74.54

Innoviva, Inc. (INVA)vs ›

$1.54B

8.03

9.12

8.67

7.22

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

OCUL Price/OCF Ratio Metrics

OCUL Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics